Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow AVIR by emailGet an email when AVIR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AVIR, unsubscribe in one click. Privacy
📣 What AVIR Says Is Next
second quarter of 2027 · “Following the recent topline readout for C-BEYOND and pending results from C-FORWARD, Atea anticipates submitting a new drug application (NDA) to the US Food & Drug Administration (FDA) in the second quarter of 2027.”
Company press release, Aug 12, 2026 · SEC filing
Q1 2027 · “Topline results are expected in early Q1 2027 and will provide additional efficacy data across a broader range of HCV genotypes more commonly found outside of the US and Canada.”
Company press release, Aug 12, 2026 · SEC filing
year-end 2026 · “C -FORWARD (conducted outside North America): Enrollment on track for completion mid-2026; topline results expected around year-end 2026.”
Company press release, May 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full AVIR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVIR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.